ME Therapeutics Holdings, Inc.
1.06
CAD
+0.01
(+0.95%)
ISIN
CA5527671054
CUSIP
552767105
Return %
Stock
S&P 500
1Y
-82.18
14.20
3Y
- -
81.12
5Y
- -
68.34
Capital Structure
CAD
•
in mil. unless spec.Working Capital
CAD
•
in mil. unless spec.Growth Rates
CAD
•
in mil. unless spec.Quarterly Revenue
CAD
•
in mil. unless spec.Quarterly Earnings Per Share
CAD
•
in mil. unless spec.Quarterly Dividends Per Share
CAD
•
in mil. unless spec.Company Description
- CEO
- Salim Zulifkar Dhanji
- Sector
- Health technology
- Industry
- Biotechnology
- Address
- Vancouver Canada
- IPO Date
- Oct 12, 2023
- Website
- metherapeutics.com
- Similar Companies
- Business
- ME Therapeutics Holdings Inc. is a preclinical-stage biotechnology company focused on the discovery and development of novel immuno-oncology therapies that reprogram the tumor microenvironment and restore the immune system's ability to combat cancer. Founded in 2021 and headquartered in Vancouver, British Columbia, Canada, the company develops targeted therapeutics designed to overcome immune suppression driven by myeloid cells, advance in vivo cell therapies, and activate innate immune pathways across oncology and autoimmune indications. The company's core product and technology portfolio is structured across four primary program areas: monoclonal antibody therapeutics, featuring h1B11-12, a high-affinity humanized antibody targeting granulocyte colony-stimulating factor (G-CSF) to block the recruitment and expansion of immunosuppressive myeloid-derived cells; myeloid-targeted prodrugs, including small-molecule candidates D094 and D099, designed to selectively deplete or modulate suppressive tumor-associated myeloid cells; in vivo chimeric antigen receptor (CAR) therapies, led by dual-targeting CD19/CD22 CAR mRNA constructs delivered via lipid nanoparticles (LNPs) to reprogram immune cells directly inside the patient's body for hematological malignancies and autoimmune disorders; and therapeutic mRNA modulators, headlined by an mRNA-based STING (Stimulator of Interferon Genes) pathway activator engineered to stimulate innate anti-tumor immunity and synergize with checkpoint inhibitors in solid tumors such as colorectal cancer; complemented by proprietary myeloid-specific lipid nanoparticle (LNP) delivery platforms for targeted nucleic acid and small-molecule delivery. In recent operational and strategic developments, ME Therapeutics has achieved significant milestones in its research pipeline, intellectual property portfolio, and corporate positioning. The company entered into an intellectual property licensing agreement with the National Research Council of Canada (NRC) to integrate a proprietary CD22 nanobody into its in vivo dual CAR program, advancing both tandem and co-expression lead candidates into comparative testing ahead of lipid nanoparticle formulation. Furthermore, the company secured patent grants in the United States and China for its lead anti-G-CSF antibody h1B11-12, initiated cell line development to support future clinical-grade manufacturing, and reported advancements in liver-detargeted formulations for its therapeutic STING mRNA asset. On the corporate and financial front, ME Therapeutics completed non-brokered private placement equity financings to fund ongoing preclinical research, and its common shares were added to the Canadian Securities Exchange's benchmark CSE25 Index under the ticker symbol METX.